ArticleInternational orthopaedics2012
Expression of Vascular Endothelial Growth Factor correlates with the advance of clinical osteosarcoma.
Article in International orthopaedics, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02711007 (A Phase II Trial of Apatinib in Relapsed and Unresectable High-grade Osteosarcoma After Failure of Standard Multimodal Therapy), which is not on this map. Cited by 29 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A Phase II Trial of Apatinib in Relapsed and Unresectable High-grade Osteosarcoma After Failure of Standard Multimodal Therapy
Who cites it
29 citing papers in PubMed, 4 syntheses or guidelines pooled it, 49 citations in OpenAlex.
- The role of vascular endothelial growth factor as a prognostic and clinicopathological marker in osteosarcoma: a systematic review and meta-analysis.Journal of orthopaedic surgery and research · 2021Pooled it
- Effects of vascular endothelial growth factor expression on pathological characteristics and prognosis of osteosarcoma.Clinical and experimental medicine · 2016Pooled it
- Vascular endothelial growth factor polymorphisms are associated with osteosarcoma susceptibility.Oncotarget · 2016Pooled it
- A systematic review of vascular endothelial growth factor expression as a biomarker of prognosis in patients with osteosarcoma.Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine · 2013Pooled it
- A CAM bioimaging model reveals the connection between VEGFA vascular remodeling and enhanced sarcoma progression via tumor secretome.Scientific reports · 2026Article
- Nanoparticles Targeting the Tumor Microenvironment for the Treatment of Osteosarcoma: Recent Progress and Perspectives.International journal of nanomedicine · 2026Review
- Advancements in research regarding the influence of the tumor microenvironment on the proliferation and metastasis of osteosarcoma (Review).Oncology letters · 2026Review
- NOTCH Signaling in Osteosarcoma.Current issues in molecular biology · 2023Review
- ETC-159, an Upstream Wnt inhibitor, Induces Tumour Necrosis via Modulation of Angiogenesis in Osteosarcoma.International journal of molecular sciences · 2023Article
- Article
- Introducing Fluorescence-Guided Surgery for Pediatric Ewing, Osteo-, and Rhabdomyosarcomas: A Literature Review.Biomedicines · 2021Review
- Review
- Review
- Caveolin-1 Expression Together with VEGF can be a Predictor for Lung Metastasis and Poor Prognosis in Osteosarcoma.Pathology oncology research : POR · 2020Article
- Review
- Article
- Does rarity mean imparity? Biological characteristics of osteosarcoma cells originating from the spine.Journal of cancer research and clinical oncology · 2017Article
- Anti-angiogenesis target therapy for advanced osteosarcoma (Review).Oncology reports · 2017Review
- Prognostic impact of blood and urinary angiogenic factor levels at diagnosis and during treatment in patients with osteosarcoma: a prospective study.BMC cancer · 2017Article
- Vascular patterning in human heterotopic ossification.Human pathology · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeOsteosarcoma is the most common primary malignancy in orthopaedic surgery. Studies suggest that expression of VEGF and high vascularity within osteosarcoma may correlate with poor prognosis. The purpose of this study was to determine whether there was a correlation of VEGF expression with clinical tumour stage and metastasis.
methodsThis retrospective case series examined 54 cases of osteosarcoma patients who were treated during a ten-year period. Relevant clinical information included age, gender, tumour location, stage, adjuvant therapy, morbidity, mortality, and tumour subtypes. The clinical information was analysed for correlation of VEGF expression and tumour prognosis. Tumour sections were examined by routine H&E and by immunohistochemistry for VEGF, CD31, and the oncogenes c-myc and c-fos.
resultsThere was a significantly positive correlation between VEGF expression and tumour stages among these cases (p < 0.01). The data also suggested a higher cancer recurrence and more frequent cases of remote metastasis in the high-VEGF group compared to the low-VEGF group. VEGF expression also positively associated with c-fos and c-myc expressions in the primary tumour sections.
conclusionThe results of this study highlight the role of VEGF in angiogenesis and tumour burden. Data also suggest the influence of VEGF may associate with the elevations of c-fos and c-myc expression. The development of novel therapies to target the VEGF pathway in osteosarcoma may lead to improved survival.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.